Randeep Singh

Array ( [id] => 20336504 [patent_doc_number] => 20250340624 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-11-06 [patent_title] => COMPOSITIONS AND METHODS FOR DETECTING AND REGULATING FIBRONECTIN-INTEGRIN INTERACTION AND SIGNALING [patent_app_type] => utility [patent_app_number] => 19/271944 [patent_app_country] => US [patent_app_date] => 2025-07-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40142 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19271944 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20288393 [patent_doc_number] => 20250313636 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-10-09 [patent_title] => ALPHA4BETA7 INTEGRIN BINDING PROTEINS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 19/245760 [patent_app_country] => US [patent_app_date] => 2025-06-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46091 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 177 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19245760 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20700278 [patent_doc_number] => 12622969 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-05-12 [patent_title] => Methods for treatment using anti-a4b7 antibody [patent_app_type] => utility [patent_app_number] => 19/230064 [patent_app_country] => US [patent_app_date] => 2025-06-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 11 [patent_no_of_words] => 26667 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 183 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19230064 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20231360 [patent_doc_number] => 20250288679 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-09-18 [patent_title] => METHODS FOR TREATMENT USING ANTI-ALPHA4BETA7 ANTIBODY [patent_app_type] => utility [patent_app_number] => 19/222996 [patent_app_country] => US [patent_app_date] => 2025-05-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26655 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 175 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19222996 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20150494 [patent_doc_number] => 20250250332 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-08-07 [patent_title] => BIOMARKER-BASED TREATMENT AND DIAGNOSTIC METHODS FOR IL-17-DEPENDENT CONDITIONS [patent_app_type] => utility [patent_app_number] => 19/187625 [patent_app_country] => US [patent_app_date] => 2025-04-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16908 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19187625 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20645834 [patent_doc_number] => 12600770 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-04-14 [patent_title] => Antibodies to connective tissue growth factor (CTGF) and uses thereof [patent_app_type] => utility [patent_app_number] => 19/065094 [patent_app_country] => US [patent_app_date] => 2025-02-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 18 [patent_no_of_words] => 55811 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19065094 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19752859 [patent_doc_number] => 20250041424 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-02-06 [patent_title] => METHODS FOR TREATMENT USING ANTI-ALPHA4BETA7 ANTIBODY [patent_app_type] => utility [patent_app_number] => 18/922371 [patent_app_country] => US [patent_app_date] => 2024-10-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30324 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 162 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18922371 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19629727 [patent_doc_number] => 20240408176 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-12-12 [patent_title] => FUSION PROTEIN COMPRISING ANTI-CD73 ANTIBODY AND IL-2, AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/815390 [patent_app_country] => US [patent_app_date] => 2024-08-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16813 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18815390 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19528212 [patent_doc_number] => 20240352114 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-24 [patent_title] => PLK1 INHIBITOR IN COMBINATION WITH ANTI-ANGIOGENICS FOR TREATING METASTATIC CANCER [patent_app_type] => utility [patent_app_number] => 18/750887 [patent_app_country] => US [patent_app_date] => 2024-06-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23536 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 144 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18750887 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19528213 [patent_doc_number] => 20240352115 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-24 [patent_title] => PLK1 INHIBITOR IN COMBINATION WITH ANTI-ANGIOGENICS FOR TREATING METASTATIC CANCER [patent_app_type] => utility [patent_app_number] => 18/750908 [patent_app_country] => US [patent_app_date] => 2024-06-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23528 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18750908 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19526597 [patent_doc_number] => 20240350499 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-24 [patent_title] => PLK1 INHIBITOR IN COMBINATION WITH ANTI-ANGIOGENICS FOR TREATING METASTATIC CANCER [patent_app_type] => utility [patent_app_number] => 18/750999 [patent_app_country] => US [patent_app_date] => 2024-06-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23519 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18750999 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19738335 [patent_doc_number] => 12215153 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2025-02-04 [patent_title] => Anti-receptor expressed on lymphoid tissues (RELT) recombinant monoclonal antibody and preparation method and use thereof [patent_app_type] => utility [patent_app_number] => 18/745750 [patent_app_country] => US [patent_app_date] => 2024-06-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 10 [patent_no_of_words] => 7236 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 76 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18745750 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19745707 [patent_doc_number] => 20250034272 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-30 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING SEVERE ASTHMA [patent_app_type] => utility [patent_app_number] => 18/739089 [patent_app_country] => US [patent_app_date] => 2024-06-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16596 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18739089 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19586422 [patent_doc_number] => 20240383979 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-21 [patent_title] => Anti-DLL3 Antibodies and Uses Thereof [patent_app_type] => utility [patent_app_number] => 18/733287 [patent_app_country] => US [patent_app_date] => 2024-06-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24503 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18733287 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19543186 [patent_doc_number] => 20240360222 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-31 [patent_title] => ANTIBODY [patent_app_type] => utility [patent_app_number] => 18/662493 [patent_app_country] => US [patent_app_date] => 2024-05-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21339 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18662493 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19448961 [patent_doc_number] => 20240309091 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-19 [patent_title] => HUMAN ANTI-SEMAPHORIN 4D ANTIBODY [patent_app_type] => utility [patent_app_number] => 18/654538 [patent_app_country] => US [patent_app_date] => 2024-05-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27932 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 110 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18654538 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19692918 [patent_doc_number] => 20250011463 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-09 [patent_title] => CONSTRUCTS TARGETING PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/640985 [patent_app_country] => US [patent_app_date] => 2024-04-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 77411 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18640985 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19403669 [patent_doc_number] => 20240287180 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-29 [patent_title] => TREATMENT OF EOSINOPHIL OR MAST CELL RELATED DISORDERS [patent_app_type] => utility [patent_app_number] => 18/634562 [patent_app_country] => US [patent_app_date] => 2024-04-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45586 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -44 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18634562 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19682410 [patent_doc_number] => 20250000955 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-02 [patent_title] => MAP44 POLYPEPTIDES AND CONSTRUCTS BASED ON NATURAL ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/614952 [patent_app_country] => US [patent_app_date] => 2024-03-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46575 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18614952 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19717368 [patent_doc_number] => 12202891 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-01-21 [patent_title] => Antibody capable of binding to thymic stromal lymphopoietin and use thereof [patent_app_type] => utility [patent_app_number] => 18/607180 [patent_app_country] => US [patent_app_date] => 2024-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 9 [patent_no_of_words] => 22523 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18607180 [rel_patent_id] =>[rel_patent_doc_number] =>)